Clinical trials: Obesity & Overweight
Healthy Participants
Relative Levels of BMS-986036 in Blood Plasma in Healthy, Overweight, and Obese Participants Following Subcutaneous Administration Via Auto-injector Versus Pre-filled Syringe
The purpose of this study is to develop an auto-injector (AI) device for the BMS-986036 subcutaneous formulation that can be self-administered conveniently by participants.
- Trial name
- NCT04493567
- Testing
- BMS-986036
- Where
- 2 sites in United States
- Volunteers
- 102 people, healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb
Overweight and Obesity
Safety and Feasibility Assessment of the Bio-electrical One Day Capsule System in Overweight and Class I Obese Participants
The study represents the first effort to prospectively investigate the Melcap's bio-electrical ingestible ODC system in human. The study goal is to evaluate the safety and feasibility of GES treatment in stomach and in the small…
- Trial name
- NCT03734081
- Testing
- ODC system (type 1 capsule), ODC system (type 2 capsule)
- Where
- Israel
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Melcap Systems Ltd.
Obesity
Feasibility Trial of ValenTx Endo Bypass System of the ValenTx Endo Bypass System in Obese Subjects
The purpose of this study is to provide initial clinical data to support the feasibility of use of the ValenTx Endo Bypass system in enhancing weight loss and co-morbidity resolution in morbidly obese subjects
- Trial name
- NCT01207830
- Testing
- Endo Bypass System
- Where
- Mexico
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- ValenTx, Inc.
Overweight, Obesity
Benefit and Tolerability of IQP-AE-103 in Weight Loss
This study is to evaluate the benefit and tolerability of two dosages of IQP-AE-103 (990mg and 1980mg daily) in reducing body weight in overweight and moderately obese subjects
- Trial name
- NCT03058367
- Testing
- IQP-AE-103 (330mg), IQP-AE-103 (165mg)
- Where
- Germany
- Volunteers
- 108 people, healthy volunteers welcome
- Sponsor
- InQpharm Group
Overweight or Obese
A Study to Evaluate MWN109 Injection in Healthy Subjects
This study is a Phase1, randomized, double-blinded, and placebo-controlled study. In each cohort, enrolled participants will be randomized to receive either placebo or MWN109.
- Trial name
- NCT06859853
- Testing
- Subcutaneous single and mutiple dose
- Where
- Australia
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Shanghai Minwei Biotechnology Co., Ltd
Obesity and Overweight
Safety and Efficacy of NA-931 and Tirzepatide in Adults Who Are Overweight or Obese
A phase 2 study to assess the efficacy of NA-931 alone or in addition to Tirzepatide to assess efficacy and safety in overweight or obese men and women
- Trial name
- NCT06732245
- Testing
- NA-931, Tirzepatide, NA-931 150 mg + no Tirzepatide
- Where
- 17 sites in United States, Australia and 1 more
- Volunteers
- 224 people
- Sponsor
- Biomed Industries, Inc.
Overweight , Obesity
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 2 Study to Evaluate the Efficacy and Safety of MWN109 Injection in Non-Diabetic Participants With Overweight or Obesity
This study is a multicenter, randomized, double-blind, placebo-controlled phase II study conducted in China. It aims to evaluate the efficacy and safety of MWN109 injection in non-diabetic participants with overweight or obesity.
- Trial name
- NCT07791654
- Testing
- MWN109 1, MWN109 2, MWN109 3
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Shanghai Minwei Biotechnology Co., Ltd
Morbid Obesity
European Union (EU) Post-Market Study on Easyband®
The purpose of this study is to collect additional safety, performance and effectiveness data of the Easyband gastric band medical device in the treatment of morbid obesity in 4 European countries where the device is a CE marked…
- Trial name
- NCT00948246
- Testing
- Easyband®
- Where
- 4 sites in Belgium, Italy and 2 more
- Volunteers
- 112 people
- Sponsor
- Allergan Medical
Pregnancy, Obesity
A Study to Evaluate Safety of Exposure to Wegovy During Pregnancy
This is an observational, prospective Wegovy (semaglutide 2.4 milligram [mg]) Pregnancy Registry Study. The aim of this study is to compare the maternal, foetal, and infant outcomes of pregnant women who are exposed to Wegovy…
- Conditions
- Pregnancy, Obesity, Overweight
- Trial name
- NCT05872022
- Testing
- No Intervention
- Where
- 3 sites in United States, Spain and 1 more
- Volunteers
- 728 people
- Sponsor
- Novo Nordisk A/S
Type 2 Diabetes Mellitus, Overweight
The TANTALUS® II System for the Treatment of Type 2 Diabetes: A Randomized Study
The main purpose of this research study is to investigate whether the TANTALUS II System is effective in improving glycemic (blood sugar) control in subjects who have type 2 diabetes (high blood sugar) and are overweight.
- Trial name
- NCT00547482
- Testing
- TANTALUS(TM) System
- Where
- 10 sites in United States
- Volunteers
- 300 people
- Sponsor
- MetaCure (USA), Inc.
Obese With Comorbidities, Obese Patients (BMI ≥ 30 kg/m²)
A Study to Investigate the Efficacy and Safety of Two Different Doses of Twice Daily Distal Jejunal-release Dextrose Beads Formulations Combined With a Gel Composition Compared to Placebos in Obese Subjects With Weight Related Comorbidities
The goal of this randomized, double-blind, placebo-controlled, phase IIa study is to demonstrate superiority on body weight reduction of two different doses of twice daily distal jejunal-release dextrose beads formulations (APHD…
- Trial name
- NCT07008456
- Testing
- APHD-012, APHD-002, APHP-012
- Where
- 6 sites in Georgia
- Volunteers
- 102 people
- Sponsor
- Aphaia Pharma US LLC
Overweight, Obesity
RCT to Compare Orlistat and Polyglucosamine for the Management of Overweight and Obesity
This trial compares two treatment methods: 1. Orlistat 60 mg to be taken three times daily one capsule; indicated for weight loss in overweight adults.
- Trial name
- NCT02529631
- Testing
- orlistat 60 mg, polyglucosamine
- Where
- 2 sites in Germany, Italy
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Certmedica International GmbH
Obesity
Sibutramine-metformin Combination Versus Sibutramine and Metformin Monotherapy in Obese Patients
The aim of this study is to evaluate the effect of sibutramine and metformin combination therapy in comparison with sibutramine or metformin monotherapy over weight, adiposity, glucose metabolism and inflammatory state in obese…
- Trial name
- NCT00941382
- Testing
- Sibutramine-Metformin, Sibutramine, Metformin
- Where
- Mexico
- Volunteers
- 60 people
- Sponsor
- Laboratorios Silanes S.A. de C.V.
Obesity
Efficacy and Safety of Ribupatide (KAI-9531) Administered Once Weekly in Participants Living With Obesity Who Do Not Have Diabetes
The primary objective of this study is to determine the effects of ribupatide administered by subcutaneous (SC) injection once weekly compared to placebo on percent change in body weight.
- Trial name
- NCT07458269
- Testing
- Ribupatide
- Where
- 35 sites in United States
- Volunteers
- 264 people
- Sponsor
- Kailera
Insulin Sensitivity, Overweight or Obesity
Pulses Consumption and Its Role in Managing Systemic Inflammation, Insulin Sensitivity and Gut Microbiome in Human
Objective 1: Characterize indices of systemic inflammation and gut microbiota composition and function after chronic (12 weeks) intake of pulses compared to control diet in human OW/OB-IR participants.
- Conditions
- Insulin Sensitivity, Overweight or Obesity, Inflammatory Response
- Trial name
- PS (NCT04267705)
- Testing
- Control, Black bean, Chickpea
- Where
- United States
- Volunteers
- 103 people, healthy volunteers welcome
- Sponsor
- Clinical Nutrition Research Center, Illinois Institute of Technology
Diabetes Mellitus, Type 2, Obesity
Pharmacodynamic Study of the Effect of INCB013739 on Insulin Sensitivity in Obese, Type 2 Diabetic Subjects
Purpose: A 28-day US study in patients with type 2 diabetes mellitus to assess the safety and tolerability as well as the effects of treatment with an investigational drug.
- Trial name
- NCT00478322
- Testing
- INCB013739
- Where
- 3 sites in United States
- Volunteers
- 24 people
- Sponsor
- Incyte Corporation
Infant Development
Effect of a New Infant Cereal on Weight Gain
The purpose of this study is to determine whether a new infant cereal has an effect on weight gain and intestinal microbiota compared to a standard cereal in healthy infants .
- Trial name
- CEOBE (NCT02165956)
- Testing
- New Infant Cereal, Standard Infant Cereal
- Where
- 5 sites in Spain
- Volunteers
- 195 people, healthy volunteers welcome
- Sponsor
- Laboratorios Ordesa
Obesity, Overweight
A Safety and Efficacy Study Comparing Naltrexone SR/Bupropion SR and Placebo in Obese Subjects With Type 2 Diabetes
The purpose of this study is determine whether the combination of naltrexone SR and bupropion SR is safe and effective in treating obesity in subjects with type 2 diabetes.
- Conditions
- Obesity, Overweight, Diabetes Mellitus, Type 2
- Trial name
- NCT00474630
- Testing
- Naltrexone SR 32 mg/bupropion SR 360 mg/ day, Ancillary therapy
- Where
- 53 sites in United States
- Volunteers
- 505 people
- Sponsor
- Orexigen Therapeutics, Inc
Insulin Resistance, Obesity
Tea-beetroot-venous Occlusion Plethysmography
In the present study, muscle perfusion will be studied before and after an oral glucose challenge following a fasting period.
- Trial name
- NCT01746329
- Testing
- Tea, Beet root
- Where
- Netherlands
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Unilever R&D
Obesity
A Long-Term Study To Examine The Effects Of CP-945,598 On Weight Loss And Safety
The purpose of this study is to examine the long-term weight loss and safety of CP-945,598 in obese adults
- Trial name
- NCT00375401
- Testing
- CP-945,598 Treatment A, CP-945,598 Treatment B
- Where
- 82 sites in United States, Canada
- Volunteers
- 2,536 people
- Sponsor
- Pfizer
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.